Insights & Analysis
Practical guidance on PBM audits, federal investigations, compounding defense, DEA enforcement, telehealth compliance, and the regulatory pressures facing pharmacies and providers nationwide.
More articles — Page 16
Page 16 of 70 · 635 articles
UPIC Audits of Toxicology and Drug Testing Labs
UPIC audits of toxicology labs turn on definitive versus presumptive testing, custom panels, and whether the ordering physician do…
Pharmacy Technician Errors That Become Audit Findings
DAW code slips, days' supply miscalculations, and refill-too-soon overrides at the technician level routinely become PBM recoupmen…
UPIC Audits of Orthotics and Prosthetics Suppliers
UPIC audits of orthotics and prosthetics suppliers turn on custom fitting documentation, proof of delivery, and referral patterns…
Zone Program Integrity Contractors: The UPIC Predecessor
ZPICs investigated Medicare fraud from 2003 to 2016, when UPICs absorbed the role. Older ZPIC-era guidance still shapes how audits…
UPIC Audits of Pain Management Practices
UPIC audits of pain management practices examine injection frequency, urine drug testing billing, and controlled substance prescri…
Debridement Frequency and Medical Necessity Challenges
How Medicare frequency checkpoints and documentation standards determine whether a repeat debridement claim survives audit review.
COVID-Era Billing Under Retrospective Review
How the Section 1135 telehealth waivers that applied during the COVID-19 Public Health Emergency affect retrospective Medicare bil…
The 60-Day Rule in Practice for Medicare Providers
CMS replaced the reasonable diligence standard for the Medicare 60-day rule in 2025. What identification means now, and the FCA ex…
Defending a Declined Qui Tam Case
A declined qui tam case is not over. The relator can litigate alone under the False Claims Act, and the government retains real op…